Syndax Pharmaceuticals Inc Uncategorized Contracts & Agreements
33 Contracts & Agreements
- Syndax Pharmaceuticals, Inc. 2023 Inducement Plan (Filed With SEC on February 27, 2024)
- Form of Option Agreement pursuant to the Syndax Pharmaceuticals, Inc. 2023 Inducement Plan (Filed With SEC on February 8, 2023)
- Syndax Pharmaceuticals, Inc. 2023 Inducement Plan (Filed With SEC on February 8, 2023)
- Amendment No. 12 to Clinical Trial Agreement by and between the Company and ECOG-ACRIN Cancer Research Group, dated May 12, 2020 (Filed With SEC on August 6, 2020)
- Amendment No. 11 to Clinical Trial Agreement by and between the Company and ECOG-ACRIN Cancer Research Group, dated July 1, 2019 (Filed With SEC on November 7, 2019)
- Amendment No. 10 to Clinical Trial Agreement by and between the Company and ECOG-ACRIN Cancer Research Group, dated October 15, 2018 (Filed With SEC on March 7, 2019)
- Amendment No. 9 to Clinical Trial Agreement by and between the Company and ECOG-ACRIN Cancer Research Group, dated November 22, 2017 (Filed With SEC on March 8, 2018)
- AMENDMENT NO. 8 TO CLINICAL TRIAL AGREEMENT BETWEEN ECOG-ACRINCANCER RESEARCH GROUP AND SYNDAX PHARMACEUTICALS, INC. (Filed With SEC on May 9, 2017)
- AMENDMENT NO. 7 TO CLINICAL TRIAL AGREEMENT BETWEEN ECOG-ACRINCANCER RESEARCH GROUP AND SYNDAX PHARMACEUTICALS, INC. (Filed With SEC on May 9, 2017)
- AMENDMENT NO. 6 TO CLINICAL TRIAL AGREEMENT BETWEEN ECOG-ACRINCANCER RESEARCH GROUP AND SYNDAX PHARMACEUTICALS, INC. (Filed With SEC on August 15, 2016)
- AMENDMENT NO. 5 TO CLINICAL TRIAL AGREEMENT BETWEEN ECOG-ACRINCANCER RESEARCH GROUP AND SYNDAX PHARMACEUTICALS, INC. (Filed With SEC on August 15, 2016)
- AMENDMENT NO. 4 TO CLINICAL TRIAL AGREEMENT E2112 BETWEEN ECOG-ACRINCANCER RESEARCH GROUP AND SYNDAX PHARMACEUTICALS, INC. (Filed With SEC on August 15, 2016)
- AMENDMENT NO. 3 TO CLINICAL TRIAL AGREEMENT BETWEEN ECOG-ACRINCANCER RESEARCH GROUP AND SYNDAX PHARMACEUTICALS, INC. (Filed With SEC on August 15, 2016)
- FIRST AMENDMENT (Filed With SEC on February 22, 2016)
- AMENDMENT NO. 2 TO CLINICAL TRIAL AGREEMENT E2112 BETWEEN ECOG-ACRIN CANCER RESEARCHGROUP AND SYNDAX PHARMACEUTICALS, INC. (Filed With SEC on February 22, 2016)
- [signature pages follow] Syndax Pharmaceuticals,Inc., 400 Totten Pond Road, Suite 110, Waltham, MA 02451 Telephone: 781 ###-###-#### Fax: 781 ###-###-#### (Filed With SEC on January 4, 2016)
- LICENSE,DEVELOPMENT AND COMMERCIALIZATION AGREEMENT Dated December 19, 2014 by and between SYNDAXPHARMACEUTICALS, INC. and KYOWA HAKKO KIRIN CO., LTD. (Filed With SEC on January 4, 2016)
- AMENDMENT NO. 1TO CLINICAL TRIAL AGREEMENT BETWEEN ECOG-ACRINCANCER RESEARCH GROUP AND SYNDAX PHARMACEUTICALS, INC. (Filed With SEC on January 4, 2016)
- CLINICAL TRIALAGREEMENT (Filed With SEC on January 4, 2016)
- LICENSE,DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (Filed With SEC on January 4, 2016)
- Exhibit A (Filed With SEC on January 4, 2016)
- LICENSE,DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (Filed With SEC on May 16, 2014)
- CLINICAL TRIALAGREEMENT (Filed With SEC on March 27, 2014)
- CONSENTAND AMENDMENT AGREEMENT (Filed With SEC on March 27, 2014)
- CONSENT AND AMENDMENT AGREEMENT (Filed With SEC on March 27, 2014)
- CONSENT AND AMENDMENT AGREEMENT (Filed With SEC on March 27, 2014)
- CONSENT AND AMENDMENT AGREEMENT (Filed With SEC on March 27, 2014)
- CONSENT AND AMENDMENT AGREEMENT (Filed With SEC on March 27, 2014)
- CONSENT AND AMENDMENT AGREEMENT (Filed With SEC on March 27, 2014)
- CONSENT AND AMENDMENT AGREEMENT (Filed With SEC on March 27, 2014)
- CONSENT AND AMENDMENT AGREEMENT (Filed With SEC on March 27, 2014)
- CONSENT AND AMENDMENT AGREEMENT (Filed With SEC on March 27, 2014)
- LICENSE,DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (Filed With SEC on March 27, 2014)
